A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9 months of treatment

Mistry, Pramod K; Lukina, Elena; Ben, Dridi Marie-Francoise; Amato, Dominick J; Baris, Hagit; Dasouki, Majed; Ghosn, Marwan; Mehta, Atul; Packman, Seymour; Pastores, Gregory M; Petakov, Milan S; Peterschmitt, Judith M

Rezultati

eNauka > Rezultati > A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9 months of treatment

Naziv:	A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9 months of treatment
Autori:	Mistry, Pramod K; Lukina, Elena; Ben, Dridi Marie-Francoise; Amato, Dominick J; Baris, Hagit; Dasouki, Majed; Ghosn, Marwan; Mehta, Atul; Packman, Seymour; Pastores, Gregory M; Petakov, Milan S; Peterschmitt, Judith M;
Godina:	2013
Publikacija:	MOLECULAR GENETICS AND METABOLISM
ISSN:	1096-7192 Molecular Genetics and Metabolism Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 108 br. 2 str. S66-S67
DOI:	10.1016/j.ymgme.2012.11.171
WoS-ID:	000314670500159
URI:	https://enauka.gov.rs/handle/123456789/825819
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Alt metrika

Dimensions

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.